Patent intelligence · US
US 7815942
Rasagiline formulations of improved content uniformity
Rasagiline formulations of improved content uniformity
Patent details — US 7815942
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 19, 2010
- Expiration
- Oct 14, 2030
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Claims
- 37
- CPC classes
- A61K, A61K31/205, A61K9/14, A61K9/2018
Quick answer
US 7815942 (Rasagiline formulations of improved content uniformity) is held by TEVA PHARMACEUTICAL INDUSTRIES, LTD.. Status: granted. Granted Oct 19, 2010. Expires Oct 14, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Expiration
- Claims
- 37
- CPC classes
- A61K, A61K31/205, A61K9/14, A61K9/2018, A61K9/2059, A61P
More from TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 7815942?
US 7815942 (Rasagiline formulations of improved content uniformity) is held by TEVA PHARMACEUTICAL INDUSTRIES, LTD.. Status: granted. Granted Oct 19, 2010. Expires Oct 14, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7815942?
TEVA PHARMACEUTICAL INDUSTRIES, LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 7815942 expire?
Our index shows an expiration date of Oct 14, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.